Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H30O3 |
Molecular Weight | 366.4941 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12CCC(=O)C=C2[C@]3([H])C[C@]3([H])[C@]4([H])[C@]1([H])CC[C@@]5(C)[C@@]4([H])[C@]6([H])C[C@]6([H])[C@]75CCC(=O)O7
InChI
InChIKey=METQSPRSQINEEU-HXCATZOESA-N
InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7625729 | https://www.ncbi.nlm.nih.gov/pubmed/23530659 | https://www.ncbi.nlm.nih.gov/pubmed/7107766 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7625729 | https://www.ncbi.nlm.nih.gov/pubmed/23530659 | https://www.ncbi.nlm.nih.gov/pubmed/7107766 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf
Drospirenone (INN, USAN), also known as 1,2-dihydrospirorenone, is a steroidal progestin of the spirolactone group. Drospirenone binds strongly to the progesterone receptor (PR) and mineralocorticoid receptor (MR), with lower affinity, to the androgen receptor (AR), and very low affinity for the glucocorticoid receptor (GR). Drospirenone is an ingredient in some birth control pills and hormone replacement therapy. In combination with ethinylestradiol it is used as contraception, and for women who want contraception it is also approved by the U.S. Food and Drug Administration (FDA) to treat vasomotor symptoms due to menopause.It is sold as a combined oral contraceptive under the brand names Yasmin (US, EU, Latin America), Jasmine (France), Yarina (Russia) in a dosage containing drospirenone 3 mg/ethinylestradiol 30 µg. In the United States, Bayer Schering released a pill based on Yasmin with the B vitamin folate (B9), which is marketed under the names Safyral and Beyaz.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7107766
Curator's Comment:: # Bayer HealthCare Pharmaceuticals
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1994 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729 |
|||
Target ID: CHEMBL208 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729 |
|||
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | YASMIN Approved UseINDICATIONS AND USAGE. Yasmin is an estrogen/progestin COC indicated for use by women to prevent pregnancy Launch Date9.8953921E11 |
|||
Primary | Angeliq Approved UseIndications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Launch Date1.12777914E12 |
|||
Primary | Angeliq Approved UseIndications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Launch Date1.12777914E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
9.85 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
33.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
27 ng/mL |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
41 ng/mL |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1007 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
140 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
506 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
6 mg single, oral dose: 6 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
25.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
1 mg single, oral dose: 1 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22680989 |
3 mg single, oral dose: 3 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
30 h |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
|
30 h |
4 mg 1 times / day steady-state, oral dose: 4 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4% |
4 mg single, oral dose: 4 mg route of administration: Oral experiment type: SINGLE co-administered: |
DROSPIRENONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Disc. AE: Premenstrual syndrome, Migraine headache... Other AEs: Premenstrual syndrome, Migraine headache... AEs leading to discontinuation/dose reduction: Premenstrual syndrome (6.7%) Other AEs:Migraine headache (1.5%) Premenstrual syndrome (13.2%) Sources: Migraine headache (10.7%) Breast discomfort (8.3%) Nausea and vomiting (4.5%) Abdominal discomfort (2.3%) Mood change (2.3%) |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Disc. AE: Weight gain, Headache... AEs leading to discontinuation/dose reduction: Weight gain (> 0.45) Sources: Headache (> 0.45) Depression (> 0.45) Menorrhagia (> 0.45) Skin disorder (> 0.45) Emotional lability (> 0.45) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Migraine headache | 1.5% Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Migraine headache | 10.7% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Premenstrual syndrome | 13.2% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Abdominal discomfort | 2.3% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Mood change | 2.3% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Nausea and vomiting | 4.5% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Premenstrual syndrome | 6.7% Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Breast discomfort | 8.3% | 3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Sources: |
healthy, 17 - 40 years n = 2837 Health Status: healthy Age Group: 17 - 40 years Sex: F Population Size: 2837 Sources: |
Depression | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Emotional lability | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Headache | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Menorrhagia | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Skin disorder | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Weight gain | > 0.45 Disc. AE |
3 mg 1 times / day steady, oral Recommended Dose: 3 mg, 1 times / day Route: oral Route: steady Dose: 3 mg, 1 times / day Co-administed with:: ethinylestradiol(20 mug) Sources: |
healthy, mean 25.1 years n = 220 Health Status: healthy Age Group: mean 25.1 years Sex: F Population Size: 220 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
minimum | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
minimum | |||
moderate [IC50 31200 uM] | no (co-administration study) Comment: "IC50 units given are ""mM""; no significant effect of DRSP on the systemic clearance of the CYP3A4 product omeprazole sulfone was found" Page: 25.0 |
|||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
moderate [IC50 36500 uM] | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
yes [IC50 14500 uM] | |||
yes [IC50 3390 uM] | no (co-administration study) Comment: "IC50 units given are ""mM""; daily oral administration of 3 mg DRSP for 14 days did not affect the oral clearance of omeprazole (40 mg, single oral dose) and the CYP2C19 product 5-hydroxy omeprazole" Page: 25.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
yes | no (co-administration study) Comment: simvastatin is not expected to affect DRSP's metabolism; When tested with midazolam, PK parameters of midazolam were similar regardless whether it was dosed with DSRP or with placebo. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021676s000_CLINPHARMR.pdf#page=25 Page: 25.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins. | 1992 Dec |
|
Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being. | 2002 Dec |
|
Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. | 2002 Dec |
|
Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone. | 2002 Nov |
|
Evolution of progestins. Focus on the novel progestin drospirenone. | 2002 Nov |
|
Update and future of systemic acne treatment. | 2003 |
|
Species, sex and inter-individual differences in DNA repair induced by nine sex steroids in primary cultures of rat and human hepatocytes. | 2003 Apr 20 |
|
A review of treatment of premenstrual syndrome and premenstrual dysphoric disorder. | 2003 Aug |
|
New contraceptive methods: update 2003. | 2003 Aug |
|
Classification and pharmacology of progestins. | 2003 Dec 10 |
|
Thromboembolism associated with the new contraceptive Yasmin. | 2003 Feb 1 |
|
Newer progestogens. | 2003 Jan |
|
A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. | 2003 Jun |
|
[Effects on the quality of life of a new oral contraceptive containing 30 mcg EE and 3 mg drospirenone (Yasmin)]. | 2003 Jun 18 |
|
Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. | 2003 Mar |
|
Conception and pharmacodynamic profile of drospirenone. | 2003 Nov |
|
Hormone therapy and the cardiovascular system: the critical role of progestins. | 2003 Oct |
|
Use of an oral contraceptive containing drospirenone in an extended regimen. | 2003 Sep |
|
New progestogens: a review of their effects in perimenopausal and postmenopausal women. | 2004 |
|
Safety of a new oral contraceptive containing drospirenone. | 2004 |
|
Enhancing oral contraceptive success: the potential of new formulations. | 2004 Apr |
|
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. | 2004 Apr |
|
A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. | 2004 Apr |
|
Pharmacological profile of progestins. | 2004 Apr 15 |
|
An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women. | 2004 Jan |
|
Rationale for new oral contraceptive dosing. | 2004 Jan-Feb |
|
An observational study of Yasmin in the management of women with polycystic ovary syndrome. | 2004 Jul |
|
Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. | 2004 Jun |
|
Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. | 2004 Jun |
|
Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis. | 2004 Mar |
|
[Medication of the month. Angeliq: new hormonal therapy of menopause, with antialdosterone and antiandrogenic properties]. | 2004 Mar |
|
Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol. | 2004 Mar |
|
Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. | 2004 Nov |
|
The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. | 2004 Nov |
|
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. | 2004 Sep |
|
New contraception options. | 2004 Sep-Oct |
|
Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. | 2005 Dec |
|
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. | 2005 Dec |
|
Drospirenone and PCOS. | 2005 Jan |
|
A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. | 2005 Jan |
|
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine"). | 2005 Jan |
|
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. | 2005 Jan |
|
Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat. | 2005 Mar |
|
Effects of drospirenone/estrogen combinations on bone metabolism. | 2005 Oct |
|
Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. | 2005 Oct |
|
Importance of controlling blood pressure. | 2005 Oct |
|
Pharmacology of different progestogens: the special case of drospirenone. | 2005 Oct |
|
The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days. | 2006 Jan |
|
Treating acne with oral contraceptives: use of lower doses. | 2006 Jan |
|
New progestagens for contraceptive use. | 2006 Mar-Apr |
Sample Use Guides
In Vivo Use Guide
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf
To prevent pregnancy: One tablet (containing 3 mg drospirenone and 0.03 mg ethinyl estradiol) daily by mouth at the same time every day.
To prevent symptoms due to menopause. one tablet (0.25 mg drospirenone/0.5 mg ethinyl estradiol) taken by mouth once daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7625729
Activity of drospirenone was investigated by transiently transfecting the human MR (pRShMR) and pMMTV-CAT into COS 1 cells. Cells were treated with 10 nmol/l aldosterone and, in addition, with increasing amounts of the drospirenone (1nM – 1 mkM). After 48 hrs cells were harvested and duplicate dishes were assayed for activity
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
G03AC10
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
||
|
WHO-ATC |
G03AA12
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
||
|
NDF-RT |
N0000011301
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
||
|
NDF-RT |
N0000175602
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
||
|
LIVERTOX |
333
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
||
|
WHO-ATC |
G03FA17
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
||
|
NCI_THESAURUS |
C776
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
||
|
WHO-VATC |
QG03FA17
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
||
|
WHO-VATC |
QG03AA12
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6519
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
11636
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | RxNorm | ||
|
C47502
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
67392-87-4
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
Drospirenone
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
N295J34A25
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
2874
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
SUB06413MIG
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
M4772
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | Merck Index | ||
|
Drospirenone
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
67392-87-4
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
68873
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
266-679-2
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
DB01395
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
1229409
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | USP-RS | ||
|
7896
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
968
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
C035144
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY | |||
|
CHEMBL1509
Created by
admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE INACTIVE (PARENT)
METABOLITE INACTIVE (PARENT)